Table 3.
Concordance in ER status between central laboratories – 35 cases included in the original set (phase 1) and 11 cases repeated at Mayo using dual antibody (phase 2)
| Mayo (single antibody) |
||
|---|---|---|
| ER IHC original seta | ER-negative | ER-positive |
| IEO (dual antibody) | ||
| ER-negative | 19 | -- |
| ER-positive | 5 | 10 |
| Not evaluable | 1 | -- |
| Mayo (dual antibody) |
||
|---|---|---|
| ER IHC (repeated set)b | ER-negative | ER-positive |
| IEO (dual antibody) | ||
| ER-negative | 3 | -- |
| ER-positive | -- | 8 |
ER estrogen receptor, IHC immunohistochemical, Mayo Mayo Clinic central laboratory, IEO European Institute of Oncology central laboratory
a
Includes 35 cases: 5 ER false-positive (locally positive/centrally negative) and 5 ER false-negative (locally negative/centrally positive) submitted from IEO to Mayo; and 20 ER false-positive and 5 ER false-negative submitted from Mayo to IEO
b
Includes 11 cases previously tested from Mayo (6 of the 20 ER false-positive and all 5 of the ER false-negative)